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Incidence, Mortality, and Imaging Outcomes of Atrial
Arrhythmias in COVID-19
Qasim Jehangir, MDa,*, Yi Lee, MDa, Katie Latack, MSb, Laila Poisson, PhDb, Dee Dee Wang, MDc,
Shiyi Song, BSb, Dinesh R. Apala, MDd, Kiritkumar Patel, MDd, Abdul R. Halabi, MDd,
Geetha Krishnamoorthy, MDa, and Anupam A. Sule, MD, PhDa,e
Atrial arrhythmias (AAs) are common in hospitalized patients with COVID-19; however,
it remains uncertain if AAs are a poor prognostic factor in SARS-CoV-2 infection. In this
retrospective cohort study from 2014 to 2021, we report in-hospital mortality in patients
with new-onset AA and history of AA. The incidence of new-onset congestive heart failure
(CHF), hospital length of stay and readmission rate, intensive care unit admission, arterial
and venous thromboembolism, and imaging outcomes were also analyzed. We further
compared the clinical outcomes with a propensity-matched influenza cohort. Generalized
linear regression was performed to identify the association of AA with mortality and other
outcomes, relative to those without an AA diagnosis. Predictors of new-onset AA were also
modeled. A total of 6,927 patients with COVID-19 were included (626 with new-onset AA,
779 with history of AA). We found that history of AA (adjusted relative risk [aRR] 1.38,
confidence interval [CI], 1.11 to 1.71, p = 0.003) and new-onset AA (aRR 2.02, 95% CI
1.68 to 2.43, p <0.001) were independent predictors of in-hospital mortality. The incidence
of new-onset CHF was 6.3% in history of AA (odds ratio 1.91, 95% CI 1.30 to 2.79, p
<0.001) and 11.3% in new-onset AA (odds ratio 4.01, 95% CI 3.00 to 5.35, p <0.001).
New-onset AA was shown to be associated with worse clinical outcomes within the propensity-matched COVID-19 and influenza cohorts. The risk of new-onset AA was higher in
patients with COVID-19 than influenza (aRR 2.02, 95% CI 1.76 to 2.32, p <0.0001), but
mortality associated with new-onset AA was higher in influenza (aRR 12.58, 95% CI 4.27
to 37.06, p <0.0001) than COVID-19 (aRR 1.86, 95% CI 1.55 to 2.22, p <0.0001). In a subset of the patients with COVID-19 for which echocardiographic data were captured,
abnormalities were common, including valvular abnormalities (40.9%), right ventricular
dilation (29.6%), and elevated pulmonary artery systolic pressure (16.5%); although there
was no evidence of a difference in incidence among the 3 groups. In conclusion, new-onset
AAs are associated with poor clinical outcomes in patients with COVID-19. © 2022
Elsevier Inc. All rights reserved. (Am J Cardiol 2022;00:1−9)

Introduction
There is a high incidence of cardiac electrophysiologic
issues in patients with COVID-19.1−3 Mechanisms for
arrhythmias and cardiac injuries in patients with COVID19 could be threefold including viral infection-related
(endothelial damage, microthrombi formation, and inflammatory cytokine storm); hypoxemia mediated tissue injury;
and the administration of arrhythmogenic medications.4
Common unintended nontherapeutic target effects of COVID 19 treatment include potassium channel blockade,
cytochrome P450 isoenzyme inhibition or activation, and
a
Department of Medicine, St. Joseph Mercy Oakland Hospital, Pontiac,
Michigan; bDepartment of Public Health Sciences, Henry Ford Hospital,
Detroit, Michigan; cDivision of Cardiology, Center for Structural Heart
Disease, Henry Ford Hospital, Detroit, Michigan; dDivision of Cardiology,
St. Joseph Mercy Oakland Hospital, Pontiac, Michigan; and eDepartment
of Informatics, St. Joseph Mercy Oakland Hospital, Pontiac, Michigan.
Manuscript received October 18, 2021; revised manuscript received and
accepted February 18, 2022.
See page 9 for disclosure information.
*Corresponding author: Tel: 610.780.5098; fax: 248-858-3244
E-mail addresses: qasimjehangir@gmail.com; qasim.jehangir001@
stjoeshealth.org (Q. Jehangir).

0002-9149/© 2022 Elsevier Inc. All rights reserved.
https://doi.org/10.1016/j.amjcard.2022.02.051

drug-drug interactions with anticoagulants; these may also
lead to the occurrence of arrhythmias.5 To further identify
the etiology of cardiac injury and arrhythmias in these
patients, transthoracic echocardiography (TTE) can be useful in directing treatment; however, because of infection
control, TTE examinations are limited. Although more
patients with COVID-19 are getting TTE than at the start of
the pandemic, the data on TTE findings in patients with
COVID-19 and particularly the impact of atrial arrhythmias
(AAs) on echocardiographic phenotypes are scarce. Moreover, data on the effect of AA on chest computed tomography (CT) findings are also limited. In this multicenter
study, we evaluated the association of new-onset and history of AA with clinical and imaging outcomes in hospitalized patients with COVID-19. The clinical outcomes are
also compared with a cohort of hospitalized patients with
influenza.

Methods
Data were collected for patients with COVID-19 and
influenza from 1 quaternary care and 5 community hospitals
at Henry Ford Health and Trinity Health systems. For
www.ajconline.org
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Figure 1. Consort diagram of Southeastern Michigan registry consortium database.

patients with COVID-19, clinical data were derived from
electronic health records that were deidentified and stored
in the Southeast Michigan COVID-19 Consortium Registry
Database (SMCRD) using REDCap. Each institution independently collected data both retrospectively and concurrently from March 1, 2020, to March 31, 2021. Adult
patients with positive SARS-CoV-2 polymerase chain reaction tests were included. Of 6,943 patients in the SMCRD
registry, 16 patients were excluded because of lack of data
on inpatient diagnoses, and 6,927 patients met the inclusion
criteria (Figure 1). Data were collected for patients hospitalized with a diagnosis of influenza (identified by International Classification of Diseases, Tenth Revision [ICD-10]
codes) at Henry Ford Health System and deidentified (Supplementary Table 1). The study period for patients with
influenza was from January 1, 2014 to December 31, 2019.
A total of 14,174 patients with influenza were included
(Supplementary Table 2). This study was approved by both
Trinity and Henry Ford health systems institutional review
boards.
Patients with AA (atrial fibrillation [AF] and atrial flutter) were identified using standardized text and ICD-10
codes. Collected data for COVID-19 and influenza populations included baseline demographics, co-morbid conditions, and in-hospital events (electronically abstracted from
standardized text variables and ICD-10 codes). For patients
with COVID-19, inpatient vital signs, laboratory values,
and medications were electronically abstracted from the
medical record. Social history, preadmission medications,
chest CT, and echocardiographic data were obtained
through manual abstraction. We studied the cumulative steroid use including methylprednisolone, dexamethasone,
and hydrocortisone. COVID-19 treatments, including azithromycin, hydroxychloroquine, tocilizumab, remdesivir,
lopinavir, and ritonavir were also recorded (Supplementary
Figure 1). Moreover, we reported inpatient rate control,
rhythm control, and anticoagulant therapies in patients with
COVID-19 (Supplementary Tables 3 to 4).
The patients in this study were divided into 3 groups:
Group 1, defined as the normal sinus rhythm (NSR) group
who remained in NSR throughout hospitalization; group 2,

defined as new-onset AA group who did not have a history
of AA but developed AF or atrial flutter during hospitalization; and group 3, defined as patients with a history of AA
and may have stayed in NSR or experienced AA during
hospitalization. The primary outcome was in-hospital mortality in 3 groups in patients with COVID-19. Secondary
outcomes included the incidence of new-onset congestive
heart failure (CHF), ventricular arrhythmias, hospital length
of stay (LOS), 90-day readmission rate, intensive care unit
(ICU) admission and LOS, rate of intubation and days on
ventilation, rate of vasopressor and inotrope use, arterial
and venous thromboembolic events, acute renal failure
(ARF), requirement for new renal replacement therapy
(RRT), bleeding events, and imaging findings including
chest CT and TTE. Major bleeding was defined per International Society on Thrombosis and Haemostasis definition.6
Bleeding (including gastrointestinal bleed, urogenital
bleeding, respiratory passages, hemothorax) that did not fit
the criteria for the International Society on Thrombosis and
Haemostasis definition of major bleeding was classified
into minor bleeding.
Summary statistics for patient characteristics were presented as medians with interquartile ranges or means with
SDs for continuous data and total numbers and percentages
for categoric data. Chi-square tests, Fisher’s exact tests,
Kruskal−Wallis test, and analysis of variance were used to
assess differences between groups. To examine whether
AAs were independently associated with the primary end
point of in-hospital mortality, multivariable generalized linear regression model using a log link with Poisson distribution (multi-parameter regression [MPR]) model was built
using baseline demographic characteristics, co-morbid conditions and presenting labs which were significantly different between the groups, and hypoxia in the emergency
room. A similar MPR was built to identify the predictors of
new-onset AA.
In the next step, we matched the COVID-19 population
to the influenza cohort, a suitable pre-COVID viral pneumonia comparator (Supplementary Figure 2). Propensity
scoring was used serially to generate balanced AA groups,
within the COVID-19 study set, within the influenza study
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Table 1
Baseline characteristics of patients with COVID-19
Variable

Age (years)*
Women
Men
Black
White
Other races
Body mass index (kg/m2)*
Smoker
Never
Current
Former
Unknown
Alcohol user
Never
Current
Former
Unknown
Marijuana user
Diabetes mellitus
Hypertension
Congestive heart failure
Coronary artery disease
Stroke/transient ischemic attack
Deep vein thrombosis
Pulmonary embolism
CHA₂DS₂-VASc ≥ 2
CHA₂DS₂-VASc ≥ 4
Pulmonary disease (COPD, asthma, bronchiectasis, interstitial lung
disease)
Pulmonary hypertension
Liver disease (alcoholic liver disease, cirrhosis, nonalcoholic steatohepatitis, hepatitis B, hepatitis C)
Sarcoidosis
Chronic kidney disease
End-stage renal disease
Solid cancer and hematological malignancy
Autoimmune disease (lupus, rheumatoid arthritis, systemic sclerosis including limited cutaneous and diffuse cutaneous, autoimmune hepatitis, other autoimmune disease)
Hyperthyroidism
Hypothyroidism
Transplant (renal, lung, liver, heart)

Normal sinus
rhythm (n = 5522)

New-onset atrial
arrhythmias
(n = 626)

History of atrial
arrythmias (n =
779)

p Value

62.7 (17)
2,877 (52%)
2,645 (48%)
2,076 (37.6%)
2,839 (51.4%)
399 (7.3%)
31.5 (8.6)

74.9 (12.4)
275 (44%)
351 (56%)
173 (27.7%)
421 (67.4%)
21 (4.7%)
30.4 (7.8)

77.3 (11.7)
362 (46.5%)
417 (53.5%)
155 (19.9%)
579 (74%)
28 (3.6%)
29.5 (7.7)

449 (59.6%)
49 (6.5%)
222 (29.5%)
33 (4.43%)

27 (34.6%)
3 (5.1%)
41 (52.6%)
7 (9%)

32 (33%)
7 (7.2%)
50 (51.6%)
8 (8.2%)

395 (52.5%)
187 (24.8%)
62 (8.2%)
109 (14.5%)
32 (4.3%)
1,929 (35%)
3,462 (62.7%)
642 (11.6%)
348 (9.8%)
n = 3548
448 (8.1%)
269 (4.9%)
208 (3.8%)
3,514 (77.2%)
1,369 (30.1%)
1,146 (20.8%)

42 (52.9%)
17 (21.8%)
5 (6.4%)
14 (18%)
1 (1.3%)
241 (38.5%)
477 (76.2%)
206 (32.9%)
68 (17.9%)
n = 380
77 (12.3%)
40 (6.4%)
12 (1.9%)
507 (91.7%)
267 (48.3%)
181 (28.9%)

59 (60.8%)
15 (15.5%)
6 (6.2%)
17 (17.5%)
5 (5.2%)
310 (39.8%)
665 (85.4%)
408 (52.4%)
115 (28.7%)
n = 401
166 (21.3%)
68 (8.7%)
38 (4.9%)
669 (95.4%)
435 (62.1%)
255 (32.7%)

<0.0001
0.0002
0.054
<0.0001
<0.0001
<0.0001

53 (1%)
137 (2.5%)

8 (1.3%)
19 (3%)

38 (4.9%)
17 (2.2%)

<0.0001
0.91

43 (0.8%)
598 (10.8%)
143 (2.6%)
767 (13.9%)
208 (3.8%)

5 (0.8%)
109 (17.4%)
23 (3.7%)
133 (21.3%)
24 (3.8%)

5 (0.6%)
195 (25%)
44 (5.7%)
190 (24.4%)
52 (6.7%)

0.91
<0.0001
0.0001
<0.0001
0.0036

16 (2.6%)
78 (12.5%)
6 (2.4%)
n = 437

31 (4%)
92 (11.8%)
6 (1.6%)
n = 339

<0.0001
0.0031
0.91

<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

0.4096

74 (1.3%)
480 (8.7%)
51 (2.6%)
n = 1674

0.4001
0.05
<0.0001
<0.0001
<0.0001

One-way ANOVA was used for age and body mass index, and chi-square were tests otherwise.
Social history (smoking, alcohol, and marijuana use) was available for 928 patients.
COPD = chronic obstructive pulmonary disease.
Bold values denote statistical significance at the p <0.05 level
* Mean (standard deviation).

set, and between the COVID-19 and influenza study sets
(Supplementary Tables 5, 6, and 7).7 Statistical analysis
was performed using R version 4.0.4 (R Foundation for Statistical Computing, Vienna, Austria).
Results
A total of 6,927 patients with COVID-19 were included
in the study; 5,522 patients (79.7%) remained in NSR
(group 1); 626 patients (9%) had new-onset AA (group 2);

whereas 779 patients (11.3%) had history of AA (group 3)
(Figure 2). The demographic characteristics of 3 groups of
patients with COVID-19 are summarized in Table 1. The
baseline characteristics of 14,174 patients with influenza
are shown in Supplementary Table 2.
Home medications of patients with COVID-19 were
reviewed, with findings of statins, b blockers, digoxin, diuretics, and antiplatelets usage more common in groups 2
and 3 (Supplementary Table 8). In multivariable generalized linear regression analysis, age (increments of 10
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Table 2
Laboratory values and presenting vital signs in 3 groups
Variable
Peak laboratory values, median
(Q1, Q3)*
Lactate dehydrogenase (U/L)
Ferritin (ng/ml)
Troponin I (ng/ml)
Creatine phosphokinase (U/L)
C-reactive protein (mg/dl)
B-type natriuretic peptide (pg/ml)
Interleukin-6 (pg/ml)
Serum creatinine (mg/dl)
Lactate (mmol/L)
Procalcitonin (ng/ml)
D-dimer (ng/ml)b
Alanine aminotransferase (U/L)
Aspartate aminotransferase (U/L)
Serum potassium (mEq/L)
Serum magnesium (mg/dl)

Normal sinus
rhythm

New-onset atrial
arrhythmias

History of atrial
arrhythmias

KruskalWallis p-value
<0.0001

317 (232, 444)
n = 4,013
487 (218, 872)
n = 4,045
0.024 (0.01, 0.06)
n = 2,431
88 (63, 217)
n = 3,930
7.1 (4, 9.2)
n = 4,026
55 (27, 117)
n = 3,016
23 (9, 65)
n = 567
1.1 (0.8, 1.6)
n = 4,591
1.5 (1.2, 2.3)
n = 1,226
0.27 (0.15, 0.79)
n = 2,292
705 (370, 1550)
n = 3,948
34 (20, 60)
n = 4,401
41 (28, 65)
n = 4,404
4.5 (4.1, 4.9)
n = 4,582
2.2 (2, 2.4)
n = 4,450

354 (244, 527)
n = 447
614 (239, 910)
n = 460
0.05 (0.02, 0.09)
n = 430
88 (61, 262)
n = 452
8.3 (5.6, 9.7)
n = 460
189 (82, 475)
n = 428
41.8 (20, 76.9)
n = 107
1.6 (1.1, 3.4)
n = 528
1.9 (1.3, 2.9)
n = 237
0.46 (0.22, 1.6)
n = 333
1190 (605, 2500)
n = 451
34 (21, 66)
n = 507
49 (31, 75)
n = 508
4.8 (4.4, 5.6)
n = 528
2.3 (2.1, 2.7)
n = 518

295 (217, 406)
n = 487
398 (167, 861)
n = 495
0.04 (0.02, 0.08)
n = 449
78 (53, 99)
n = 478
7,6 (4.2, 9.5)
n = 496
249 (110, 532)
n = 482
41 (11.8, 102)
n = 81
1.4 (1, 2.5)
n = 589
1.8 (1.3, 2.7)
n = 215
0.34 (0.17, 1)
n = 319
850 (410, 1720)
n = 493
27 (17, 46)
n = 563
39 (27, 61)
n = 563
4.7 (4.3, 5.3)
n = 589
2.2 (2, 2.4)
n = 576

3 (2.6, 3.4)
n = 4,401
3.6 (3.3, 3.9)
n = 4,582
1.9 (1.7, 2)
n = 4,450
0.6 (0.4, 0.9)
n = 4,644
11.7 (10.4, 12.9)
n = 4,676

2.6 (2.1, 3)
n = 508
3.6 (3.2, 3.9)
n = 528
1.8 (1.6, 1.9)
n = 518
0.4 (0.2, 0.7)
n = 525
10.7 (10.1, 12.2)
n = 528

2.8 (2.3, 3.2)
n = 562
3.6 (3.2, 3.9)
n = 589
1.8 (1.6, 1.9)
n = 576
0.5 (0.3, 0.8)
n = 588
11 (10.1, 12.5)
n = 590

<0.0001

132 (118, 148)
n = 4,698
74 (65, 84)
n = 4,698
2221 (43.6%)

131 (112,147)
n = 528
70 (60, 81)
n = 528
321 (56.5%)

132 (115,149)
n = 590
72 (61, 82)
n = 590
313 (46.8%)

0.0563

0.0009
<0.0001
<0.0001
<0.0001
<0.0001
0.0034
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001

Lowest laboratory values,
median (Q1, Q3)*
Albumin (g/dL)
Serum potassium (mEq/L)
Serum magnesium (mg/dl)
Lymphocyte count (K/UL)
Hemoglobin (gm/dl)
Presenting clinical signs
Systolic blood pressure (mmHg)*
Diastolic blood pressure (mmHg)*
c

Hypoxia

0.42
<0.0001
<0.0001
<0.0001

<0.0001
<0.0001

Bold values denote statistical significance at the p <0.05 level
* Median (interquartile range).
b
Fibrinogen-equivalent units (FEU)
c
Oxygen saturation <95%

years), male gender, White race, history of coronary artery
disease, CHF, end-stage renal disease, presenting leukocytosis, hypermagnesemia, and hypomagnesemia were independently associated with the occurrence of AA
(Supplementary Table 9).
Patients with new-onset AA had higher peaks of myocardial injury marker (troponin I) and inflammatory markers
including lactate dehydrogenase, ferritin, C-reactive protein, procalcitonin, D-dimer, interleukin-6, and aspartate
aminotransferase and more pronounced lymphopenia,

hypoalbuminemia, and hyperkalemia compared with
patients with history of AA and NSR (Table 2). Among 123
patients who underwent chest CT, with results abstracted
for the SMCRD, 59.4% had ground-glass opacities and
multifocal pneumonia (n = 73), 20.3% had pleural effusion
(n = 25), and 2.4% had pleural effusions or pulmonary vascular congestion (n = 3) (Supplementary Table 10). The
prevalence of pleural effusion was highest in group 3
(group 1 13.8%, group 2 13.3%, group 3 54.6%, p = 0.02)
with no significant difference in the prevalence of other
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Table 3
Echocardiographic findings in patients with COVID-19
Variable
Right ventricular size
Normal
Mildly enlarged
Moderately enlarged
Severely enlarged
Unknown
Left ventricular size
Normal
Mildly enlarged
Moderately enlarged
Severely enlarged
Unknown
Left ventricular ejection fraction
Reduced (<40%)
Borderline (40 - 49%)
Preserved (≥50%)
Unknown
Pericardial effusion
None
Small
Moderate
Large
Unknown
Valvular abnormality
None
Mild
Moderate
Severe
Unknown
Pulmonary artery systolic pressure
Normal (0−40 mm Hg)
Mild elevation (41−50 mm Hg)
Moderate elevation (51−60 mm Hg)
Severe elevation (>60 mm Hg)
Unknown

Normal sinus
rhythm (n = 84)

New-onset atrial
arrhythmias (n = 20)

History of atrial
arrhythmias (n = 11)

54 (64.3%)
14 (16.7%)
8 (9.5%)
4 (4.8%)
4 (4.8%)

13 (65%)
2 (10%)
2 (10%)
0
3 (15%)

5 (45.5%)
4 (36.4%)
0
0
2 (18.2%)

0.68

74 (88.1%)
5 (6%)
0
0
5 (6%)

16 (80%)
1 (5%)
0
0
3 (15%)

9 (81.8%)
0
0
1 (9.1%)
1 (9.1%)

0.68

7 (8.3%)
5 (6%)
70 (83.3%)
2 (2.4%)

5 (25%)
3 (15%)
10 (50%)
2 (10%)

3 (27.3%)
0
8 (72.7%)
0

0.129

70 (83.3%)
6 (7.1%)
1 (1.2%)
1 (1.2%)
6 (7.1%)

15 (75%)
3 (15%)
0
0
2 (10%)

8 72.7%)
1 (9.1%)
0
0
2 18.2%)

0.68

49 (58.3%)
22 (26.2%)
6 (7.1%)
3 (3.6%)
4 (4.8%)

8 (40%)
9 (45%)
1 (5%)
0
2 (10%)

3 (27.3%)
5 (45.5%)
1 (9.1%)
0
2 (18.2%)

0.68

38 (45.2%)
5 (6%)
4 (4.8%)
5 (6%)
32 (38.1%)

13 (65%)
2 (25%)
1 (5%)
0
4 (20%)

7 (63.6%)
1 (9.1%)
1 (9.1%)
0
2 (18.2%)

0.68

findings among the 3 groups. The most common TTE
abnormalities were valvular abnormalities (40.9%), right
ventricular dilation (29.6%), elevated pulmonary artery systolic function (16.5%), reduced left ventricular (LV) ejection fraction (13.9%), pericardial effusion (10.4%), and LV
dilation (6.1%) with no significant difference in the prevalence of these echocardiographic abnormalities among the
3 groups (Table 3).
Among all patients, 61.8% (N=1507) received corticosteroids during hospitalization; group 2 (group that
developed new-onset AA) received steroids more frequently than the other 2 groups (group 2 vs 3 vs 1,
61.8% vs 49.4% vs 51.8%, p <0.0001) (Supplementary
Figure 1). Remdesivir, azithromycin, and hydroxychloroquine usage were more frequent in the NSR group.
Rhythm control therapy was used more frequently in
patients with new-onset AA than those with a history of
AA (Supplementary Table 3). A total of 76.6% of
patients with new-onset AA and 76.4% with history of
AA received therapeutic doses of anticoagulation (Supplementary Table 4).

Fisher-exact
p-value

We analyzed in-hospital events among 3 groups
(Table 4). Group 3 had 6.3% patients with new-onset CHF
(n = 49) versus 11.3% in group 2% (n = 71) and 3.1% in
group 1 (n = 171) (p <0.001). Ventricular tachycardia (VT)
and ventricular fibrillation were more common in group 2
and 3 than group 1. Group 2 had a longer hospital LOS than
the other 2 groups. Group 2 had worse outcomes in terms of
higher rate of intubation, vasopressor/ionotropic support,
and ICU admission and LOS than the other groups. Group
2 also had more complications including non−ST-elevation
myocardial infarction, deep vein thrombosis, ARF, and
need for new RRT. The incidences of transient ischemic
attack, ischemic stroke, arterial thromboembolism, and
major and minor bleeding were also higher in group 2
and 3.
The all-cause in-hospital mortality was 39.6% in group 2
(n = 248), 25.16% in group 3 (n = 196), and 11.61% in
group 1 (n = 641). In MPR model, history of AA (adjusted
relative risk [aRR] 1.38, confidence interval [CI] 1.11 to
1.71, p = 0.003) and newly detected AA (aRR 2.02, 95% CI
1.68 to 2.43, p <0.001) were independently associated with
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Table 4
In-hospital events in 3 groups of patients with COVID-19
Variable

New-onset atrial
arrhythmias

History of
atrial arrhythmias
Group 3 vs group 1

Group 2 vs group 1

Group 2 vs group 3

5.1 (3.1, 8.9)
1089 (19.7%)
7 (3, 13)
444 (8%)
569 (10.3%)

8.1 (4.8, 15.1)
282 (45%)
9 (4, 16)
43 (6.9%)
178 (28.4%)

6.4 (4.1, 11.7)
206 (26.4%)
5 (3, 12)
99 (12.7%)
99 (12.7%)

1.02 (1.01-1.03) <0.001
1.46 (1.23-1.74) <0.001
0.99 (0.97-1.00) 0.14
1.67 (1.32-2.10) <0.001
1.27 (1.01-1.59) <0.001

1.04 (1.04-1.05) <0.001
3.34 (2.81-3.96) <0.001
1.01 (1.00-1.03) 0.02
0.84 (0.61-1.17) 0.304
3.46 (2.85-4.20) <0.001

1.03 (1.02-1.04) <0.001
2.28 (1.82-2.85) <0.001
1.03 (1.01-1.05) 0.006
0.51- (0.35-0.74) <0.001
2.73 (2.08-3.59) <0.001

8 (4, 14)
759 (13.8%)
171 (3.1%)
100 (1.8%)

9 (5, 16)
228 (36.4%)
71 (11.3%)
20 (3.2%)

8 (3, 14)
195 (25%)
49 (6.3%)
39 (5%)

0.99 (0.97-1.01) 0.309
2.10 (1.75-2.51) <0.001
2.10 (1.51-2.91) <0.001
2.86 (1.96-4.17) <0.001

1.01 (0.99-1.02) 0.275
3.59 (3.00-4.30) <0.001
4.01 (3.00-5.35) <0.001
1.79 (1.10-2.91) 0.019

1.02 (1.00-1.05) 0.11
1.72 (1.36-2.16) <0.001
1.91 (1.30-2.79) <0.001
0.63 (0.36-1.09) 0.095

21 (0.4%)

4 (0.6%)

N/A

1.68 (0.58-4.92) 0.34

N/A

303 (5.5%)

105 (16.8%)

91 (11.7%)

2.28 (1.78-2.92) <0.001

3.47 (2.73-4.41) <0.001

1.52 (1.13-2.06) 0.006

94 (1.7%)
179 (3.2%)
233 (4.22%)
1669 (30.2%)
128 (2.3%)

24 (3.8%)
35 (5.6%)
35 (5.6%)
325 (51.9%)
37 (5.9%)

42 (5.4%)
19 (2.4%)
22 (2.8%)
339 (43.5%)
23 (3.0%)

3.29 (2.27-4.77) <0.001
0.75 (0.46-1.21) 0.23
0.66 (0.42-1.03) 0.066
1.78 (1.53-2.07) <0.001
1.28 (0.82-2.01) 0.279

2.30 (1.46-3.63) <0.001
1.77 (1.22-2.56) 0.003
1.34 (0.93-1.94) 0.11
2.49 (2.11-2.95) <0.001
2.65 (1.82-3.86) <0.001

0.70 (0.42-1.17) 0.17
2.37 (1.34-4.18) 0.003
2.04 (1.18-3.51) 0.01
1.40 (1.13-1.73) 0.002
2.06 (1.21-3.51) 0.007

11 (0.2%)
90 (1.6%)
330 (6%)
517 (9.4%)

7 (1.1%)
41 (6.6%)
93 (14.9%)
117 (18.7%)

2.59 (0.82-8.14) 0.104
3.79 (2.63-5.45) <0.001
1.63 (1.25-2.12) <0.001
1.71 (1.38-2.12) <0.001

5.67 (2.19-14.67) <0.001
4.23 (2.90-6.18) <0.001
2.75 (2.15-3.53) <0.001
2.23 (1.79-2.78) <0.001

2.19 (0.64-7.52) 0.617
1.12 (0.72-1.73) 0.212
1.69 (1.22-2.34) 0.002
1.30 (0.98-1.72) 0.067

4 (0.5%)
46, 5.9%
73 (9.4%)
117 (15%)

Odds ratios were calculated for each 2-group comparison using univariate logistic regression.
Group 1: normal sinus rhythm; group 2: new-onset atrial arrhythmias; group 3: history of atrial arrhythmias.
* Median (interquartile range).
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Hospital length of stay*
Intensive care unit admission
Intensive care unit length of stay*
Hospital readmission within 90 days
Respiratory failure requiring
mechanical ventilation
Days on ventilator*
Vasopressors/inotropes usage
New-onset congestive heart failure
Transient ischemic attack and ischemic stroke
ST-segment elevation myocardial
infarction
Non−ST-segment elevation myocardial infarction
Other arterial thromboembolism
Deep vein thrombosis
Pulmonary embolism
Acute renal failure
Renal failure requiring new renal
replacement therapy
Ventricular fibrillation
Ventricular tachycardia
Major bleeding
Minor bleeding

Normal sinus
rhythm
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higher in-hospital mortality (Supplementary Table 11), relative to those with NSR. The 90-day readmission rate in
new-onset AA was lower than in patients with history of
AA and NSR, which could be possibly explained by the
higher mortality in patients with new-onset AA. Among
patients with influenza, the in-hospital mortality was 6.3%
in group 2 (n = 22), 1.3% in group 3 (n = 20), and 0.7% in
group 1 (n = 81).
After propensity matching across the AA groups and 2
study cohorts, the clinical trends in patients with COVID19 remained similar with new-onset AA associated with
higher ICU admission, rate of intubation, usage of vasopressors and inotropes, new-onset CHF, non−ST-elevation
myocardial infarction, ARF, and VT. Likewise, in patients
with influenza, new-onset AA were associated with higher
ICU admission, rate of intubation, usage of vasopressors
and inotropes, incidence of new-onset CHF, STEMI, VT,
and ventricular fibrillation, and need for new RRT (Supplementary Tables 12 to 13). In a separate analysis, the risk of
inpatient mortality for patients with influenza was higher in
history of AA than NSR (aRR 12.58, 95% CI 4.27 to 37.06,
p <0.0001), which was not the case for patients with
COVID-19 (aRR 1.15, 95% CI 0.92 to 1.42, p = 0.2429).
The risk of inpatient mortality associated with new-onset
AA compared with NSR was higher in both influenza and
COVID-19 cohorts, with the risk higher in influenza (aRR
12.58; 95% CI 4.27 to 37.06, p <0.0001) than in COVID19 (aRR 1.86, 95% CI 1.55 to 2.22, p <0.0001). However,
the risk of new-onset AA in hospitalized patients with
COVID-19 was higher than patients with influenza (aRR
2.02, 95% CI 1.76 to 2.32, p <0.001).
Discussion
This is a comprehensive study of patients with COVID19 categorized into 3 groups based on electrophysiologic
status with a comparison of the outcomes among the 3
groups. We report a 20.3% prevalence of AA in a large
cohort (n = 6,927). The pathophysiology in COVID-19
infection, including cytokine storm, endotheliitis, and systemic infection, causing hemodynamic instability is hypothesized to be associated with a higher incidence of new-onset
AA.4,8 The prevalence of AA was lower in the influenza
cohort at 13.1% with a lower incidence of new-onset AA
(2.5%) than in COVID-19 (9%); this could be due to the
less severe inflammatory response of influenza infection
and frequent usage of steroids which are the standard of
care for hypoxic patients with COVID-19.
AAs are the most common sustained cardiac rhythm disorder in critically ill patients and those with sepsis.9−11
AAs are common in patients with COVID-19 with variable
incidence. The prevalence of AF was 19% among hospitalized patients with COVID-19 in an Italian study and 36%
in patients with cardiac disease, AF was more common in
patients who died (42.1% vs 32.5% in survivors).12 In the
United States, the prevalence of AA is reported from 15.8%
to 19.6% across different academic centers.1−3,13 The
higher prevalence (20.3%) of AA in our cohort could be
explained by the larger size of our study cohort, the larger
epidemic surge in Michigan compared with other regions,
necessitating stricter admission criteria leading to the
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admission of patients with advanced COVID-19 disease,
and thereby increased usage of steroids.
In hospitalized patients with COVID-19, AAs were
independently associated with higher in-hospital mortality (aRR 1.46, 95% CI 1.34 to 1.59 in 1 study13 and
adjusted odds ratio [OR] 1.93, 95% CI 1.20 to 3.11 in
the other2). In our study, we found that both history of
AA and new-onset AA were independently associated
with in-hospital mortality. New-onset AAs were associated with a more severe course of the disease and are
potentially a marker of severe systemic COVID-19 illness. Likewise, both new-onset AA and history of AA
were associated with a higher mortality in patients with
influenza. Compared to COVID-19, patients with influenza with new-onset AA had an even higher risk of
mortality (aRR 12.58, 95% CI 4.27 to 37.06 vs 1.86,
95% CI 1.55 to 2.22); although because of the low mortality numbers in the influenza cohort, this finding
should be explored in future clinical studies.
Our COVID-19 cohort had a high incidence of ICU
admission and myocardial infarction. In this analysis,
the incidence of new-onset CHF was 4.2% (n = 291).
Patients with new-onset AA had the highest odds of
new-onset CHF (OR 4.01, 95% CI 3.00 to 5.35, p
<0.001), followed by patients with history of AA (OR
1.91, 95% CI 1.30 to 2.79, p <0.001). A similar trend
was seen in patients with COVID-19 and influenza after
matching between the 2 cohorts. The association of both
AA and CHF was appreciated more than a decade ago
and AAs may exacerbate the development of decompensated CHF.14,15
Respiratory viruses like influenza have the potential to
trigger decompensated CHF and lead to increased mortality.15−17 A study showed a decrease in LV function in
patients with severe acute respiratory syndrome coronavirus; the impairment was worse in more critically ill
patients.18 A Chinese study found that the incidence of
CHF was higher in COVID-19 nonsurvivors than survivors
(52% vs 12%).19 Another smaller COVID-19 study
(n = 21) in the United States reported cardiomyopathy in 1/
3 of the critically ill patients.20 The exact mechanism of
tachycardia-induced cardiomyopathy is not well defined.15
Animal models have suggested that myocardial ischemia,
myocardial energy depletion, abnormalities in calcium regulation, and extracellular matrix remodeling could be the
underlying mechanisms.21
RECOVERY (Randomized Evaluation of COVID-19
Therapy) trial showed lower 28-day mortality in patients
with COVID-19 who received dexamethasone, leading
to the recommendation of steroid use by COVID-19
treatment guidelines.22 We defined steroid (including
methylprednisolone, dexamethasone, and hydrocortisone)
use during hospitalization to reach clinically significant
cumulative effect and looked for association with incidence of AA (Supplementary Figure 1). All subtypes of
steroids usage were more common in the new-onset AA
group, followed by history of AA. This suggests an
association between high-dose steroid use and the incidence of new-onset AA, although causality cannot be
determined. Some studies have suggested an increased
incidence of AF in patients receiving high-dose
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Figure 2. Central illustration. aRR, adjusted relative risk; CI, confidence interval; LV, left ventricle; OR, odds ratio; PASP, pulmonary artery systolic pressure; RV, right ventricle

corticosteroids, whereas others suggest a preventive
effect of steroids.23−27 Although corticosteroids are currently the first-line treatment for hypoxic patients with
COVID-19, their use could be associated with an
increased risk of developing AA because of their potential arrhythmogenic effect in patients with COVID-19.
Our study has both strengths and limitations. The
strengths include a large sample size, multicenter-based
data, availability of complete outcome events data, and
comparison to a large matched cohort of patients with
influenza. Limitations are the observational study design
and the inherent risk of bias from unregistered confounders. Since we did not examine the exact onset of
AA in our cohort, the temporal relation between arrhythmia onset and in hospital outcomes was not examined.
Because our follow-up only extended to hospital

discharge, the occurrence and impact of AA after hospitalization is not known. Also, we did not examine the
cause of death in the patients who died.
In conclusion, new-onset AAs are a poor prognostic
marker in hospitalized patients with COVID-19. AAs
occurred in 20.3% of hospitalized patients with COVID19 and 13.1% of patients with influenza. Compared with
influenza, the risk of new-onset AA was higher in
COVID-19; whereas new-onset AA were associated with
a higher risk of mortality in influenza. The incidence of
new-onset CHF was higher in patients with new-onset
AA than patients with NSR in both cohorts. Previous or
new-onset atrial AA did not increase the prevalence
of echocardiographic abnormalities in patients with
COVID-19.
Figure 2
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